Cancer in Young Adults Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Conditions: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma Intervention: Drug: Atezolizumab Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
Conditions: Solid Tumor; Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma Intervention: Drug: Alectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
Conditions: Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma Intervention: Drug: Entrectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Conditions: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma Intervention: Drug: Atezolizumab Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
Conditions: Solid Tumor; Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma Intervention: Drug: Alectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
Conditions: Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma Intervention: Drug: Entrectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Conditions: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma Intervention: Drug: Atezolizumab Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
Conditions: Solid Tumor; Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma Intervention: Drug: Alectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
Conditions: Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma Intervention: Drug: Entrectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Conditions: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma Intervention: Drug: Atezolizumab Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
Conditions: Solid Tumor; Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma Intervention: Drug: Alectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
Conditions: Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma Intervention: Drug: Entrectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Conditions: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma Intervention: Drug: Atezolizumab Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
Conditions: Solid Tumor; Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma Intervention: Drug: Alectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
Conditions: Solid Tumor; Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma Intervention: Drug: Entrectinib Sponsors: Cancer Research UK; University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2023 Category: Research Source Type: clinical trials
